ライフサイエンスコーパス: nonmyeloablative

1 recipients received BALB/c bone marrow under nonmyeloablative (3 Gy) and minimal (1 Gy) total body ir

2 isease currently limit the implementation of nonmyeloablative allo HSCT.

3 Recent results, however, indicate that nonmyeloablative allo-HSCT in adult patients with SCD al

4 -CSF-secreting tumor cells in the setting of nonmyeloablative allogeneic bone marrow transplantation.

5 ses of fludarabine and rituximab (BFR), as a nonmyeloablative allogeneic conditioning regimen for pat

6 ietic cell transplantation (HCT) followed by nonmyeloablative allogeneic HCT (auto/alloHCT) provides

7 VCA can be established through simultaneous nonmyeloablative allogeneic HCT and VCA transplantation

8 Nonmyeloablative allogeneic HCT can produce durable dise

9 Here, we examined outcomes after nonmyeloablative allogeneic HCT in such patients.

10 rial combined autologous HCT with subsequent nonmyeloablative allogeneic HCT to maintain the benefits

11 ng patients aged 60 to 75 years treated with nonmyeloablative allogeneic HCT, 5-year overall and prog

12 We examined the outcome of nonmyeloablative allogeneic hematopoietic cell transplan

13 A protocol for nonmyeloablative allogeneic hematopoietic stem-cell tran

14 We used nonmyeloablative allogeneic HSCT to treat a 52-year-old

15 pe with or without thalassemia who underwent nonmyeloablative allogeneic HSCT, the rate of stable mix

16 Two patients who had undergone nonmyeloablative allogeneic stem cell transplantation 53

17 08, we reported favorable 5-year outcomes of nonmyeloablative allogeneic stem cell transplantation af

18 inally, enthusiasm has focused on the use of nonmyeloablative allogeneic stem cell transplantation an

19 We performed a nonmyeloablative allogeneic stem cell transplantation on

20 Nonmyeloablative allogeneic stem-cell transplantation (a

21 These data suggest that nonmyeloablative allogeneic stem-cell transplantation is

22 tic stem cell transplantation, followed by a nonmyeloablative allogeneic transplant.

23 Nonmyeloablative allogeneic transplantation (NMAT) infre

24 Nonmyeloablative allogeneic transplantation and high-dos

25 Nonmyeloablative allogeneic transplantation should be co

26 In the older CLL patients, nonmyeloablative allogeneic transplants are better toler

27 Nonmyeloablative allogeneic transplants are less effecti

28 has not been investigated in the setting of nonmyeloablative allografting.

29 logous HSCT for SSc have been concluded: the nonmyeloablative American Systemic Sclerosis Immune Supp

30 (RRTs) and nonrelapse mortality (NRM) in 73 nonmyeloablative and 73 myeloablative recipients of HLA-

31 lls facilitate bone marrow engraftment under nonmyeloablative and irradiation-free conditioning thera

32 y promotes allogeneic TDBM engraftment under nonmyeloablative and irradiation-free fludarabine phosph

33 , patients without comorbidities both in the nonmyeloablative and myeloablative cohorts had comparabl

34 for prospective randomized trials comparing nonmyeloablative and myeloablative conditioning regardle

35 Nonmyeloablative and reduced-intensity HCT have promised

36 s induced in NOD mice through radiation-free nonmyeloablative anti-CD3/CD8 conditioning and infusion

37 etic cell transplantation (IUHCT) is a novel nonmyeloablative approach that results in donor-specific

38 These nonmyeloablative approaches may allow extension of this

39 Stem cell transplantation, including nonmyeloablative approaches, are being incorporated into

40 ent BALB/c mice conditioned with ablative or nonmyeloablative approaches.

41 s-host disease (GVHD) may be different after nonmyeloablative as compared with myeloablative hematopo

42 forward genetic approach in a mouse model of nonmyeloablative BM transplantation.

43 ve important and unexpected implications for nonmyeloablative BMT for SCD.

44 at 20 wk compared with untreated mice, while nonmyeloablative BMT mice had significantly reduced path

45 the most important benchmark for cure after nonmyeloablative BMT.

46 We developed a nonmyeloablative bone marrow transplantation platform us

47 deficient SCID is unique in its responses to nonmyeloablative bone marrow transplantation, which has

48 Nonmyeloablative busulfan conditioning before administra

49 Administration of nonmyeloablative chemotherapeutic agents or total body i

50 Although nonmyeloablative chemotherapy alone showed an objective

51 ic melanoma suggested that conditioning with nonmyeloablative chemotherapy before adoptive transfer o

52 reduced-intensity total body irradiation or nonmyeloablative chemotherapy conditioning regimens.

53 ocytes to metastatic melanoma patients after nonmyeloablative chemotherapy has resulted in persistenc

54 or-infiltrating lymphocytes (TILs) following nonmyeloablative chemotherapy mediates tumor regression

55 c disease, were randomly assigned to receive nonmyeloablative chemotherapy with or without 1,200 cGy

56 The analysis of 4 trials employing nonmyeloablative chemotherapy with or without total body

57 gous stem cell transplantation (HDC/ASCT) or nonmyeloablative chemotherapy, the former supported by s

58 yelotoxicity and prolonged neutropenia after nonmyeloablative chemotherapy.

59 significantly better 5-year EFS and OS than nonmyeloablative chemotherapy; cis-RA given after consol

60 O arm, but not during the first month in the nonmyeloablative cohort starting rhEPO on D0.

61 ificantly different among patients receiving nonmyeloablative compared with myeloablative conditionin

62 eukemia (AML) and myelodysplasia (MDS) after nonmyeloablative compared with myeloablative conditionin

63 iagnosed with advanced CLL were treated with nonmyeloablative conditioning (2 Gy total-body irradiati

64 wk of age using MHC-matched donor cells and nonmyeloablative conditioning (550 cGy irradiation).

65 Invasive mold infections occurred late after nonmyeloablative conditioning (median, day 107), with pr

66 = 165), reduced intensity (RIC; n = 143), or nonmyeloablative conditioning (NMAC; n = 88) regimens.

67 ortality among 60 consecutive patients given nonmyeloablative conditioning (nonablative patients) to

68 We demonstrate that nonmyeloablative conditioning achieves mixed hematopoiet

69 nt long-term benefit when patients are given nonmyeloablative conditioning and ADA enzyme-replacement

70 administration of HAART was feasible during nonmyeloablative conditioning and after HCT.

71 nolate mofetil, was first demonstrated after nonmyeloablative conditioning and allografting using hum

72 In the present studies, we demonstrate that nonmyeloablative conditioning and BM cell infusion modul

73 sm was transient, which was most common with nonmyeloablative conditioning and fully rather than hapl

74 patients with advanced CLL when treated with nonmyeloablative conditioning and hematopoietic cell tra

75 Four of five dogs with CLAD that received nonmyeloablative conditioning and infusion of autologous

76 equency and severity of hepatic injury after nonmyeloablative conditioning and its relationship to ou

77 Eight monkeys underwent nonmyeloablative conditioning and major histocompatibili

78 Baboon BMT to treat AIDS was attempted using nonmyeloablative conditioning and resulted in transient

79 established lupus-like disease that received nonmyeloablative conditioning and transplants of (MHC) h

80 In the present studies, we used a nonmyeloablative conditioning approach to establish chim

81 hese findings support the use of UCB after a nonmyeloablative conditioning as a strategy for extendin

82 Thus, tailoring the intensity of nonmyeloablative conditioning based on prior chemotherap

83 ties of overall survival of 41% and 29% with nonmyeloablative conditioning compared with 45% and 24%

84 all survival at 2 years of 70% and 57% after nonmyeloablative conditioning compared with 78% and 50%

85 matopoietic cell transplantation (HCT) after nonmyeloablative conditioning consisting of 2 Gy total b

86 Mixed chimeras prepared with low-intensity nonmyeloablative conditioning exhibit systemic tolerance

87 shed in mismatched kidney recipients through nonmyeloablative conditioning followed by infusion of a

88 e mechanism for total body irradiation-based nonmyeloablative conditioning for BM transplantation, an

89 matopoietic cell transplantation (HCT) after nonmyeloablative conditioning for hematologic malignanci

90 versus-host disease (GVHD) prophylaxis after nonmyeloablative conditioning for HLA class I or II mism

91 gs have uncomplicated parturitions following nonmyeloablative conditioning for SCT.

92 Nonmyeloablative conditioning has significantly reduced

93 plantation of purified allogeneic HSCs after nonmyeloablative conditioning has the potential to rever

94 matopoietic cell transplantation (HCT) after nonmyeloablative conditioning in 64 patients who had adv

95 bone marrow and kidney transplant following nonmyeloablative conditioning in a patient with multiple

96 and consider reduced intensity conditioning/nonmyeloablative conditioning in patients who have achie

97 matopoietic cell transplantation (HCT) after nonmyeloablative conditioning in patients with hematolog

98 outcomes were seen with allogeneic HCT after nonmyeloablative conditioning in selected patients who h

99 Mixed chimerism established by nonmyeloablative conditioning induces long-term acceptan

100 Allogeneic HCT after nonmyeloablative conditioning is a promising salvage str

101 Although the major role for nonmyeloablative conditioning is to control alloreactive

102 oablative regimens suggested that the use of nonmyeloablative conditioning might be associated with l

103 ematopoietic stem cell transplantation after nonmyeloablative conditioning might become the procedure

104 s-leukemia effects, and allogeneic HCT after nonmyeloablative conditioning might prolong median survi

105 The role of allogeneic transplant with nonmyeloablative conditioning needs to be explored furth

106 CI, 1.39-13.81]), and in the late phase were nonmyeloablative conditioning regimen (HR, 35.08 [95% CI

107 rsus-host disease (GVHD) in mice receiving a nonmyeloablative conditioning regimen allowing establish

108 arrow transplantation using a short-duration nonmyeloablative conditioning regimen and posttransplant

109 We have used a nonmyeloablative conditioning regimen consisting of tota

110 issue of Blood, Muller et al showed, using a nonmyeloablative conditioning regimen consisting of tota

111 Here, we ask whether a nonmyeloablative conditioning regimen establishing mixed

112 afts undergoing this complete short-duration nonmyeloablative conditioning regimen had durable lung a

113 ound for nearly all patients, we have used a nonmyeloablative conditioning regimen in conjunction wit

114 Using a GVHD protective nonmyeloablative conditioning regimen of total lymphoid

115 oxp3+ regulatory T cells (Tregs) surviving a nonmyeloablative conditioning regimen that undergo robus

116 Twenty-one animals received a nonmyeloablative conditioning regimen.

117 irradiation (TBI) were compared as part of a nonmyeloablative conditioning regimen.

118 Recent clinical reports suggest that nonmyeloablative conditioning regimens afford better out

119 Nonmyeloablative conditioning regimens are increasingly

120 This has prompted the recent development of nonmyeloablative conditioning regimens for allogeneic he

121 s (SMNs) in the era of reduced-intensity and nonmyeloablative conditioning regimens for hematopoietic

122 ens, and they provide support for the use of nonmyeloablative conditioning regimens in preclinical pr

123 re, our studies suggest the possibility that nonmyeloablative conditioning regimens might be effectiv

124 inition of high-dose, reduced-intensity, and nonmyeloablative conditioning regimens, the most commonl

125 treatment-related mortality associated with nonmyeloablative conditioning regimens, the question of

126 oviral-mediated gene therapy in CLAD using 2 nonmyeloablative conditioning regimens--200 cGy total bo

127 ols in cases of limited graft cell number or nonmyeloablative conditioning regimens.

128 PS was significantly lower at 120 days after nonmyeloablative conditioning than conventional conditio

129 Nonmyeloablative conditioning using total lymphoid irrad

130 ing the first year after allogeneic HCT with nonmyeloablative conditioning were 19%, 15%, 14%, and 5%

131 c stem cell (HSC) engraftment following this nonmyeloablative conditioning were evaluated.

132 Patients given nonmyeloablative conditioning were older than those give

133 Patients receiving nonmyeloablative conditioning were older, more frequentl

134 The results suggest that nonmyeloablative conditioning with (213)Bi-labeled anti-

135 Nonmyeloablative conditioning with 200 cGy TBI and anti-

136 nt study, we tested BDDpfVIII activity after nonmyeloablative conditioning with busulfan, cyclophosph

137 opoietic chimerism can be achieved following nonmyeloablative conditioning with cyclophosphamide, T c

138 ed and refractory mantle cell lymphoma after nonmyeloablative conditioning with fludarabine and 2 Gy

139 Nonmyeloablative conditioning with posttransplantation h

140 hematopoietic stem cell transplantation, and nonmyeloablative conditioning with total lymphoid irradi

141 ific tolerance can be achieved with mPBMC in nonmyeloablative conditioning without GVHD.

142 ression analysis: use of 2 UCB units, use of nonmyeloablative conditioning, and absence of antithymoc

143 In a canine model of allogeneic HCT after nonmyeloablative conditioning, DST to skin grafts was ev

144 Seventy-one patients received nonmyeloablative conditioning, fludarabine (30 mg/m(2)/d

145 blative conditioning but is persistent after nonmyeloablative conditioning, in which recipient hemato

146 ity was estimated at 22% (36 patients) after nonmyeloablative conditioning, of which 39% (14 patients

147 In summary, following nonmyeloablative conditioning, simultaneous administrati

148 In murine mixed chimeras prepared with nonmyeloablative conditioning, we previously showed that

149 t factor predicting lessened RRT and NRM was nonmyeloablative conditioning, whereas high pretransplan

150 jections occurred after reduced-intensity or nonmyeloablative conditioning, which associated with poo

151 sed risk of failure of engraftment following nonmyeloablative conditioning.

152 = .009) and better survival (P = .04) after nonmyeloablative conditioning.

153 improve survival after allogeneic HCT after nonmyeloablative conditioning.

154 itumor responses similar to those seen after nonmyeloablative conditioning.

155 ng cells, was infused into the patient after nonmyeloablative conditioning.

156 e disappearance of gene-modified cells after nonmyeloablative conditioning.

157 163 patients undergoing allogeneic HCT with nonmyeloablative conditioning.

158 ns (RLIs) to mixed chimeras established with nonmyeloablative conditioning.

159 in 21% receiving myeloablative vs. 12% with nonmyeloablative conditioning.

160 entical living-related donors after modified nonmyeloablative conditioning.

161 Many patients received nonmyeloablative conditioning; a significant proportion

162 o investigate the effect of a pharmacologic, nonmyeloablative, conditioning regimen on the developmen

163 VCN and enhanced early human chimerism under nonmyeloablative conditions, thus representing an optima

164 fficient to induce long-term tolerance under nonmyeloablative conditions.

165 , 2 doses of PS-341 (0.5 mg/kg), or a single nonmyeloablative dose of 153-Sm-EDTMP (22.5 MBq) were 21

166 adhesion deficiency that were treated with a nonmyeloablative dose of 200 cGy total body irradiation

167 mals or Artemis knockout mice treated with a nonmyeloablative dose of Busulfan.

168 1)I-tositumomab therapy at patient-specific, nonmyeloablative doses is safe and effective in treatmen

169 olving status of this therapeutic regimen at nonmyeloablative doses.

170 ation, double umbilical cord blood units and nonmyeloablative engraftment strategies have attracted f

171 Novel nonmyeloablative fludarabine-based preparative regimens

172 Patients in the nonmyeloablative group were older, had more previous tre

173 We initiated a clinical trial of nonmyeloablative haploidentical stem-cell transplantatio

174 rhEPO to start on day (D)28, patients given nonmyeloablative HCT (NMHCT) with rhEPO to start on D28,

175 Nonmyeloablative HCT aims to eradicate the malignancy wi

176 donor T-cell chimerism after unrelated donor nonmyeloablative HCT and suggest that targeting MPA Css'

177 However, the patients who receive the nonmyeloablative HCT are older individuals who are not e

178 ticipated that a lower risk of ARF exists in nonmyeloablative HCT as a result of the milder precondit

179 study enrolled patients who were undergoing nonmyeloablative HCT at four major centers from 1998 to

180 developing ARF that requires dialysis after nonmyeloablative HCT is infrequent despite the older age

181 These data suggest that nonmyeloablative HCT may form the basis for future clini

182 D45 or anti-TCRalphabeta as conditioning for nonmyeloablative HCT minimizes toxicity without compromi

183 e agent as prophylaxis in patients receiving nonmyeloablative HCT or ATG in the conditioning regimen.

184 Nonmyeloablative HCT resulted in a median survival of 5

185 trials using radioimmunotherapy with Bi for nonmyeloablative HCT seem feasible.

186 Novel antitumor agents combined with nonmyeloablative HCT should be explored among patients w

187 tinuing all systemic immunosuppression after nonmyeloablative HCT with HLA-matched related grafts.

188 id malignancies had high relapse rates after nonmyeloablative HCT.

189 RF in a large group of patients who received nonmyeloablative HCT.

190 e that ARF may contribute to mortality after nonmyeloablative HCT.

191 can be immunologically eradicated following nonmyeloablative HCT.

192 immunosuppressive treatment after allogeneic nonmyeloablative hematopoietic cell transplantation (HCT

193 ug mycophenolate mofetil (MMF) is used after nonmyeloablative hematopoietic cell transplantation (HCT

194 Using a canine model of nonmyeloablative hematopoietic cell transplantation (HCT

195 tent, relapsed, or progressive disease after nonmyeloablative hematopoietic cell transplantation.

196 deficiency-I facilitated development of new nonmyeloablative hematopoietic stem cell transplant and

197 l 1997 through January 2005 in an autologous nonmyeloablative hematopoietic stem cell transplantation

198 Among patients with relapsing-remitting MS, nonmyeloablative hematopoietic stem cell transplantation

199 We performed nonmyeloablative hematopoietic stem cell transplantation

200 Nonmyeloablative hematopoietic stem cell transplantation

201 he safety and clinical outcome of autologous nonmyeloablative hematopoietic stem cell transplantation

202 n patients who reject donor grafts following nonmyeloablative hemopoietic cell transplantation.

203 mice (Atm(-/-)) using a clinically relevant, nonmyeloablative host-conditioning regimen can be used t

204 In the setting of allogeneic nonmyeloablative HSC transplants (HSCTs), stable mixed c

205 l cell carcinoma (RCC) in patients following nonmyeloablative HSCT consistent with a graft-versus-tum

206 We performed nonmyeloablative HSCT in 6 patients with a newly describ

207 Nonmyeloablative HSCT in GATA2 deficiency results in rec

208 In treatment-refractory SLE, autologous nonmyeloablative HSCT results in amelioration of disease

209 udy of patients with relapsing-remitting MS, nonmyeloablative HSCT, compared with DMT, resulted in pr

210 ecreting tumor cells early after allogeneic, nonmyeloablative HSCT.

211 ) T cells in the blood of patients following nonmyeloablative HSCT.

212 Forty-eight patients underwent nonmyeloablative HSCT.

213 Nonmyeloablative induction of mixed chimerism followed b

214 These can be tolerized by nonmyeloablative induction of mixed chimerism using alph

215 Nonmyeloablative induction of mixed hematopoietic chimer

216 ther through cell transfer or survival after nonmyeloablative irradiation.

217 rtality of less than 1% (2/220 patients) for nonmyeloablative, less than 2% (3/197) for dose-reduced

218 nation with rV-4-1BBL in the setting of host nonmyeloablative lymphodepletion represents a logical st

219 del of dog leukocyte antigen (DLA)-identical nonmyeloablative marrow transplantation including postgr

220 state cancer treated by transplantation of a nonmyeloablative MHC-matched, single Y chromosome-encode

221 = 391) or MDS (n = 186) who received either nonmyeloablative (n = 125) or myeloablative (n = 452) al

222 or chronic lymphocytic leukemia given either nonmyeloablative (n = 152) or myeloablative (n = 68) con

223 patients who underwent allogeneic HSCT after nonmyeloablative (n = 183) compared with conventional (n

224 neic hematopoietic cell transplantation with nonmyeloablative (n=23) or myeloablative (n=25) conditio

225 Is) and reduced intensity conditioning (RIC)/nonmyeloablative (NMA) conditioning hematopoietic cell t

226 To better define outcomes of nonmyeloablative (NMA) HLA-haploidentical BMT with PTCy,

227 undergoing UCB transplantation with an MA or nonmyeloablative (NMA) preparative regimen.

228 its of reduced intensity conditioning (RIC), nonmyeloablative (NMA) transplant, T-cell depletion and

229 Recent advances in nonmyeloablative (NMA), related HLA-haploidentical blood

230 = 611), reduced-intensity (RI; N = 160), and nonmyeloablative (NMA; N = 161).

231 with leukemia has led to the development of nonmyeloablative or "low-intensity" conditioning regimen

232 loid malignancies who received HCT following nonmyeloablative or reduced-intensity conditioning.

233 Nonmyeloablative patients were at higher risk than ablat

234 Further, nonmyeloablative patients with comorbidities had favorab

235 ed, T-cell-depleted (1-2 x 10(4) T cells/kg) nonmyeloablative peripheral blood stem cell transplantat

236 hed living related donors, with the use of a nonmyeloablative preparative regimen.

237 Nonmyeloablative preparative therapy with MEDI-507 and h

238 ctly demonstrate the importance of providing nonmyeloablative pretransplantation conditioning to achi

239 tal body irradiation (TBI) or an established nonmyeloablative protocol (anti-CD154, anti-CD8 mAbs, an

240 lymphocytes (i.e., lethal irradiation) or a nonmyeloablative protocol that depleted peripheral CD8 c

241 ite survival can be achieved by the use of a nonmyeloablative protocol.

242 erance in adult recipients using a nontoxic, nonmyeloablative protocol.

243 a regimen that models human GVHD-protective nonmyeloablative protocols using TLI and antithymocyte g

244 The nonmyeloablative regimen consisted of 90 mg/m2 fludarabi

245 bilical cord blood (UCB) in the setting of a nonmyeloablative regimen consisting of fludarabine (200

246 All animals conditioned with the nonmyeloablative regimen developed multilineage peripher

247 ffective and less toxic than CP as part of a nonmyeloablative regimen for the induction of mixed chim

248 We tested a nonmyeloablative regimen of mAb S5 and 200 cGy TBI with

249 ven in the genetic absence of T reg cells, a nonmyeloablative regimen substantially augmented CD8+ T

250 y high-dose total body irradiation (TBI) the nonmyeloablative regimen together with cytotoxic agents

251 A minimally toxic nonmyeloablative regimen was developed for allogeneic he

252 ras generated using either lethal TBI or the nonmyeloablative regimen were tolerant to donor skin gra

253 autologous, lentivirus-transduced BM using a nonmyeloablative regimen.

254 eriod, and supports the use of this agent in nonmyeloablative regimens

255 ly reduced toxicity of allotransplants using nonmyeloablative regimens (mini-allotransplantations) ma

256 Nonmyeloablative regimens for allogeneic hematopoietic c

257 In conclusion, nonmyeloablative regimens had lower RRT and NRM and coul

258 Depleting host immune elements with nonmyeloablative regimens prior to the adoptive transfer

259 cell transplantation after myeloablative or nonmyeloablative regimens suggested that the use of nonm

260 Nonmyeloablative regimens were 2 Gy total body irradiati

261 ory antibodies under either myeloablative or nonmyeloablative regimens.

262 orbidity and mortality, including the use of nonmyeloablative regimens.

263 igher mortality risks after high-dose versus nonmyeloablative regimens.

264 , 85.7% of recipients survived when 660-cGy (nonmyeloablative) regimens were used, and 60% of recipie

265 f IUHCT to induce DST, followed by postnatal nonmyeloablative same donor "booster" bone marrow (BM) t

266 Sixty-five patients underwent nonmyeloablative stem cell transplant with ATG, TBI 200

267 Nonmyeloablative stem cell transplantation (NST) is incr

268 Nonmyeloablative stem cell transplantation in patients w

269 xed hematopoietic chimerism after allogeneic nonmyeloablative stem cell transplantation, we used this

270 We performed nonmyeloablative stem-cell transplantation in adults wit

271 We investigated the safety and efficacy of nonmyeloablative stem-cell transplantation in these pati

272 ogic neoplasms, both in myeloablative and in nonmyeloablative therapeutic strategies.

273 or marrow transplantation whereas the use of nonmyeloablative therapy has effectively reduced transpl

274 Nonmyeloablative therapy using haploidentical family mem

275 In preclinical models nonmyeloablative TLI conditioning alters residual host T

276 As in the preclinical models, nonmyeloablative TLI conditioning significantly altered

277 odulatory dendritic cells are expanded after nonmyeloablative TLI/ATS conditioning and allogeneic BMT

278 he tumor-bearing mice were lymphodepleted by nonmyeloablative total body irradiation or a myeloablati

279 ft and host survival after conditioning with nonmyeloablative total body or total lymphoid irradiatio

280 We showed previously that nonmyeloablative total lymphoid irradiation/rabbit anti-

281 stem cell transplantation (IUHCT) is a novel nonmyeloablative transplant approach that takes advantag

282 duction of transplant-related mortality with nonmyeloablative transplant approaches, rates of acute a

283 lating precursors even after minimally toxic nonmyeloablative transplant conditioning.

284 In a nonmyeloablative transplant model where GVHD lethality i

285 In particular nonmyeloablative transplant strategies using unrelated d

286 5 years with severe disease enrolled in this nonmyeloablative transplant study, consisting of alemtuz

287 ificantly delayed donor LC-engraftment after nonmyeloablative transplantation compared with other hem

288 Nonmyeloablative transplantation has been attempted with

289 Although nonmyeloablative transplantation is expected to reduce t

290 Nonmyeloablative transplantation may provide an effectiv

291 Efforts to use nonmyeloablative transplantation strategies in adults lo

292 Clinical application of nonmyeloablative transplantation thus requires knowledge

293 s) with severe sickle cell disease underwent nonmyeloablative transplantation with CD34+ peripheral-b

294 des a platform for future clinical trials of nonmyeloablative transplantation with radioimmunotherapy

295 the question of reproductive function after nonmyeloablative transplantation, we analyzed a cohort o

296 It is unclear if nonmyeloablative transplants are more effective than aut

297 In most recipients of nonmyeloablative transplants, recipient LCs proliferated

298 of subset depletion of DLIs in recipients of nonmyeloablative transplants.

299 will focus on clinical outcomes, results of nonmyeloablative UCBT, graft-versus-leukemia effect and

300 er active investigation in both ablative and nonmyeloablative unrelated-donor stem cell transplantati